PATH Malaria Vaccine Initiative and Crucell to test new malaria vaccine approach
LEIDEN, The Netherlands, July 29, 2009 The US-based PATH Malaria Vaccine Initiative (MVI), the United States Agency for International Development (USAID) Malaria Vaccine Development Program (MVDP), and Dutch biopharmaceutical company Crucell
N.V. today announced a collaboration to accelerate deve...
DSM and Crucell Sign Agreement with Avid Bioservices to Serve as First Pre-Approved U.S. Contract Manufacturer of PER.C6(R) Cell Line Proteins
LEIDEN, Netherlands and PARSIPPANY, N.J., June 25 /PRNewswire/ -- DSM
Biologics and Crucell
N.V. (Euronext, Nasdaq: CRXL; Swiss Exchange: CRX)
announced today that they have entered into an agreement with Avid
Bioservices, Inc. of Tustin, California to join their Vendor Network. Under
Sanofi Pasteur Enters Agreement With Crucell for Next-Generation Biologicals Against Rabies
Exclusive Agreement for Rabies Monoclonal Antibodies to Fight Fatal Disease
LYON, France, January 3 /PRNewswire-FirstCall/ -- Sanofi Pasteur, the
vaccines division of sanofi-aventis Group, announced today that it has
signed an exclusive collaboration and commercialization agreement with
Flu virus foiled again
...ersal influenza vaccine.
The Scripps research team, led by Ian A. Wilson, Ph.D., in collaboration with researchers at the biopharmaceutical company crucell
Holland (The Netherlands), discovered the potent antibody during a systematic examination of blood samples taken from healthy individuals who previous...
Boston Trial to Test New HIV/AIDS Vaccine
...V/AIDS vaccine candidates.
The vaccine, the first HIV-1 vaccine candidate to emerge from the IPCAVD program, is made by Dutch biotechnology company crucell
The approach used in developing the rAd26 vaccine enables researchers to circumvent preexisting immunity to serotype 5, the virus resp...
Clinical trial will test new HIV/AIDS vaccine
...sion of AIDS, National Institute of Allergy and Infectious Diseases, National Institutes of Health.
Manufactured by the Dutch biotechnology company crucell
Holland BV, the rAd26 vaccine is the first HIV-1 vaccine candidate to emerge from the IPCAVD initiative, which brings together investigators from acad...
Sanofi-aventis Announces 2007 Earnings Ahead of Guidance Sharp Rise in Proposed Dividend
...f alliance agreements with Regeneron, Acambis, crucell
and Oxford Biomedica, and buyout of rights to ...ron, Oxford BioMedica (TroVax(R)),
UCB (Xyzal(R)), crucell
N.V. and Acambis.
Acquisitions of investments (e...I (to develop a
new tuberculosis vaccine) and with crucell
(in monoclonal rabies
antibodies), plus an allianc...
Crucell's Rabies MAb Enters Phase I Trial in India
... Dutch biotechnology company, crucell
N V’s Rabies monoclonal antibody (mAb) product has entered a phase I clinical study in India, four months after launching// a similar study in the US....
Crucell in Medical Technology
Aeras, Crucell and South African Tuberculosis Vaccine Initiative Announce Encouraging Preliminary Results of Tuberculosis Vaccine Clinical Trial in South Africa
ATLANTA, April 9, 2008 /PRNewswire-USNewswire/ -- Dutch biotechnology
N.V., the Aeras Global TB Vaccine Foundation and the South
African Tuberculosis Vaccine Initiative (SATVI) present a progress update
and immunology data from a Phase I Ad35 tuberculosis vaccine study at th...
ProFibrix Steps up Recombinant Fibrinogen Program With PER.C6(R) License From Crucell
LEIDEN, The Netherlands, January 13 /PRNewswire/ -- ProFibrix B.V., today
announced that it has concluded a commercial license agreement with Crucell
N.V. (Euronext, NASDAQ: CRXL ; Swiss Exchange: CRX) for PER.C6(R), a unique
human protein production platform. The PER.C6(R) platform allows P...
DSM Announces Yield Boosts of 5-10 Fold With XD(R) Technology for Mammalian Manufacturing Platforms
... In addition to offering world-class biopharmaceutical manufacturing services, DSM Biologics has co-exclusive rights, along with Dutch biotech company crucell
N.V., to license the high-producing PER.C6(R) human cell line as a production platform for recombinant proteins and monoclonal antibodies. The combina...
Sanofi Pasteur Initiates Phase II Trial of Cell Culture-Based Seasonal Influenza Vaccine
...l line, licensed from
Dutch biotechnology company, crucell
N.V. PER.C6 Cell technology offers
Sanofi Pasteur ...ion
can be found at http://www.lonza.com . About crucell crucell
N.V. is a Dutch biotechnology company (Euronext, N...
Crucell in Biological Technology
DSM and Crucell Sign Agreement with Bioceros to Serve as Pre-Approved Cell Line Generation Partner of PER.C6(R) Cell Line Proteins
LEIDEN, The Netherlands, and PARSIPPANY, N.J., Feb. 10 /PRNewswire/ -- DSM Biologics and Crucell
N.V. (Euronext, Nasdaq: CRXL ; Swiss Exchange: CRX) announced today that they have entered into an agreement with Bioceros B.V. of Utrecht, The Netherlands to join their Vendor Network. Under the ter...
DSM Biologics and Crucell Announce Commercial PER.C6(R) Licensing Agreement with Gedeon Richter
PARSIPPANY, N.J. and LEIDEN, Netherlands, Nov. 25 /PRNewswire/ -- DSM
Biologics, a business unit of DSM Pharmaceutical Products, and Dutch
biotechnology company Crucell
N.V. (Euronext, Nasdaq: CRXL ; Swiss Exchange:
CRX), today announced that Hungary-based Gedeon Richter Plc. signed a
DSM and Crucell Announce Another Key Achievement for PER.C6(R) Technology; Scale Up of High-Titer Fed-Batch Process to 250 Liters
GRONINGEN and LEIDEN, Netherlands and PARSIPPANY, N.J., Sept. 29
/PRNewswire/ -- DSM Biologics and Crucell
N.V. (Euronext, Nasdaq: CRXL;
Swiss Exchange: CRX) announced today that the high-titer fed-batch process
developed at the PERCIVIA PER.C6(R) Development Center, their joint venture
World Nanomedicine Market to Cross $160 Billion by 2015, According to New Report by Global Industry Analysts, Inc.
...ayers. Major market participants in the nanomedicine market include Abraxis BioScience Inc., AMAG Pharmaceuticals Inc, Arrowhead Research Corporation, crucell
N.V., Flamel Technologies S.A., Elan Corporation Plc, Enzon Pharmaceuticals Inc., Life Technologies Corporation, Nanosphere Inc., Nektar Therapeutics,...
KBI Biopharma Starts Cell Line Generation Process under Vendor Network Agreement for PER.C6(R)
...hon added, "Our KBI scientific team has extensive experience producing cell lines in microbial, insect and mammalian systems and are very pleased that crucell
and DSM have recognized our expertise by selecting KBI as a Partner for their Vendor Network."
KBI is now proud to offer the PER.C6(R) technolog...
Peregrine Pharmaceuticals Reports Financial Results for the First Quarter of Fiscal Year 2009
-- Avid Bioservices became the first U.S. pre-approved contract
manufacturer for licensees of the DSM Biologics and crucell
line, a proprietary high yield cell line with important advantages over
-- Received a Staff Determination letter fr...
DSM Biologics and MorphoSys AG to Manufacture Fully Human Antibody
rights, along with Dutch biotech company crucell
N.V., to license the
high-producing PER.C6(R) huma...hat are difficult to
predict and therefore DSM and crucell
do not guarantee that their
expectations will be realized. Furthermore, DSM and crucell
obligation to update the statements contai...